Onconova Therapeutics, Inc. (ONTX) announced Tuesday that it has acquired Trawsfynydd Therapeutics, Inc., a privately-held biotechnology company developing antivirals for influenza, COVID and other infectious diseases, in an all-stock transaction.
Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet needNEWTOWN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) (GLOBE NEWSWIRE) Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that a late-breaking abstract studying rigosertib in patients with recessive dystrophic epidermolysis bullosa (R
Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call Transcript August 10, 2023 Onconova Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.2, expectations were $-0.29. Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Second Quarter [Technical Difficulty] Dr. Steve Fruchtman: Sarah, excuse me, you are coming in and out […]